Navigation Links
AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
Date:11/3/2008

QUEBEC CITY, Nov. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that it has entered the second stage of patient recruitment for its Phase 2 trial in endometrial cancer with AEZS-108, a luteinizing hormone-releasing hormone (LHRH) agonist linked to doxorubicin. The decision to enter the second stage of patient recruitment was taken following recent first stage data reporting 1 complete response (CR) and 2 partial responses (PR) among 14 patients with a diagnosis of disseminated endometrial cancer. The trial is part of a Phase 2 program in gynaecological cancers for which patient enrolment began in December 2007. The open-label, non-comparative multi-center Phase 2 program will treat up to 82 women with LHRH-receptor positive ovarian and endometrial cancerous tumors. The primary endpoint for the program is the partial or complete tumor response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) and/or Gynaecologic Cancer Intergroup (GCIG) guidelines. The program is being conducted in 15 centers in Europe under the supervision of lead investigator, Prof. Gnter Emons, M.D., of the Georg-August-University, Institute of Gynaecology and Obstetrics in Gttingen, Germany.

On October 2, 2008, the Company announced it had entered the second stage of patient recruitment, this time for the Phase 2 trial in ovarian cancer of this very same program, after first stage data had shown two partial responses (PR).

Paul Blake, M.D., Senior Vice President and Chief Medical Officer of AEterna Zentaris commented, "We are very pleased with this additional data on the early signal of potential efficacy of our l
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... American Indians largely were wiped out by diseases such ... to the New World by European explorers., One report ... in the Americas shortly before Europeans arrived, and roughly ... But new research led by anthropological geneticists Anne Stone ... University of Tubingen in Germany indicates the diagnosis of ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, Inc. ... a conference call to provide an update on ... Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) ... web cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference ... completion through September 2, 2014 at (888) 203-1112 ...
(Date:8/20/2014)... Mass. , Aug. 20, 2014  Decision Resources Group finds ... , Russia , India ... $1.6 billion in 2013, roughly equal to the size of ... however, the BRIC market will experience much faster growth as a ... aging population. Other key findings from Decision Resources Group,s ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 The ... is being held on October 29-30 in San ... from industry, academic and government researchers and clinicians focused ... the space. , In the twelve years since ... hundred therapies have been introduced with pharmacogenetic information in ...
Breaking Biology Technology:Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3Neurotrope To Host Conference Call 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 36th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2
... (OTCBB:IAGX) announced today it has appointed Bill Toomey to ... the appointment, Mr. William Spencer, Imagenetix Chief Executive Officer ... join our board and bring to us his extensive ... benefit greatly from his past experiences and high level ...
... BELL, Pa., June 30, 2011 Inovio Pharmaceuticals, Inc. ... the development of therapeutic and preventive vaccines against cancers ... compelling immune responses in a study of its multi-subtype ... proprietary vaccine delivery technology in sheep, the second large ...
... ORLEANS, June 29, 2011 Ochsner Health System has signed ... e ICU Program to enhance critical care -- a program ... of stay and save lives. As the only healthcare provider ... Ochsner will serve as a statewide resource to community and ...
Cached Biology Technology:Imagenetix, Inc. Appoints Bill Toomey to Its Board of Directors 2Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 2Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 3Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 4Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 5Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 6Ochsner Health System will Offer First eICU Program in Louisiana 2Ochsner Health System will Offer First eICU Program in Louisiana 3
(Date:8/20/2014)... suffered concussions ready to return to action? A new ... athletes who head back on the field with medical ... their abilities to simultaneously walk and do simple mental ... their balance and/or altered walking speed, was found in ... returned to activity in less than a month. Seven ...
(Date:8/20/2014)... few years, Virginia Tech,s Wu Feng has built upon ... the "Computing in the Cloud" program, and synergistically complemented ... award from the Air Force on "big computing" for ... the National Institutes of Health on "big data" for ... "parallel computing" aspects from each grant, he was able ...
(Date:8/20/2014)... A new gene therapy developed by researchers at ... shown to protect mice from a life-threatening heart condition ... new therapeutic avenue," said Yi Lai, Ph.D., the leading ... the MU School of Medicine,s Department of Molecular Microbiology ... we hope this could lead to a treatment for ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Gene therapy protects mice from lethal heart condition, MU researchers find 2
... Ranganathan, professor of pharmacology at UT Southwestern Medical Center, was ... in research by The Academy of Medicine, Engineering and Science ... of one of three 2009 Edith and Peter O,Donnell Awards ... Ranganathan is director of the Systems Biology Division of the ...
... This release is available in German . ... only a single proton. If a neutron is added, ... deuterium in place of hydrogen atoms are chemically identical. ... water with molecules that contain deuterium in place of ...
... When extremes of drought and flood come in rapid succession, ... on the sequence of those events, according to a new ... The study, which focused on tree species common to the ... and were less likely to die when subjected to drought ...
Cached Biology News:UT Southwestern scientist honored among best in Texas research 2UT Southwestern scientist honored among best in Texas research 3Heavy pyridine crystallizes differently 2Sequence matters in droughts and floods 2